09.10.2017 • NewsDede WillamsCovestroBayer

Bayer Cedes Control of Covestro

(c) Covestro
(c) Covestro

Through the sale of an additional 6.9% of engineering plastics producer Covestro for €1 billion, Bayer has ceded control of its former group company known earlier as Bayer MaterialScience.

Under a control termination agreement that took effect from Sept. 30, Bayer will refrain from exercising certain voting rights at the Covestro annual general meeting, so that the plastics company will no longer be fully consolidated in the former parent’s consolidated financial statements.

Covestro will be reported as a discontinued operation in Bayer’s financial reporting for the third quarter of 2017. For continuing operations, Bayer’s key figures, including sales, EBITDA before special items, EBIT and core earnings per share, will be adjusted retrospectively to exclude Covestro’s contributions.

In addition, all assets and liabilities allocated to Covestro will not be included in Bayer’s statement of financial position as of Sept. 30, 2017. The remaining Covestro interest will be carried at the current market value, and, from Oct. 1, 2017, accounted for using the equity method.

With the share sale, Bayer has taken a major step toward its goal of a full separation from Covestro in the medium term, CEO Werner Baumann said.  The former parent company’s stakeholding is now only 24.6%, but the Bayer Pension Trust continues to hold 8.9%.

Buyers of the Covestro shares have agreed to a lock-up arrangement that stipulated they may not be sold before Dec. 11, 2017 at the earliest. Bayer said it will retain economic exposure to the price of these shares until at least the same date.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
08.08.2025 • News

Carbios und Indorama kooperieren bei rPET

Carbios wird recycelte Monomere bereitstellen, die von Indorama Ventures zu Filamenten für die Verstärkung von Reifen des Herstellers Michelin verarbeitet werden.

Photo
19.05.2025 • NewsChemie

OQ Chemicals firmiert künftig wieder als Oxea

Der bis Mai 2020 unter dem Namen Oxea bekannte Hersteller von Oxo-Zwischenprodukten und Oxo-Derivaten, der zwischenzeitlich zum Omanischen Energieunternehmen OQ gehörte und unter dem Namen OQ Chemicals firmierte, kehrt zu seinem alten Namen und seinen Wurzeln zurück.